Nuvalent NUVL
NUVL
$123.96 +0.00 (+0.00%)
At close: Jul 21, 2026 · 4:00 PM EDT

Nuvalent (NUVL) Cash from Financing Activities (2020 - 2026)

Nuvalent's (NUVL) quarterly Cash from Financing Activities came in at $9.8 million in Q1 2026, up 115.5% YoY from $4.5 million in Q1 2025, and down 98.04% on a QoQ basis from $500.3 million in Q4 2025.

Analysis

Nuvalent (NUVL) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Nuvalent (NUVL) has 7 years of Cash from Financing Activities data on file, last reported at $9.8 million in Q1 2026.

  • Quarterly Cash from Financing Activities rose 115.5% year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $520.6 million (down 8.26% YoY) and the FY2025 annual result came in at $515.3 million, down 9.41% from the prior year.
  • Cash from Financing Activities eased to $9.8 million in Q1 2026, from $500.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $550.3 million in Q3 2024 to a low of -$768000.0 in Q1 2022.
  • A 5-year average of $98.8 million and a median of $4.8 million in 2025 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 107.68% — and 2024, when it jumped 35311.76%.
  • Tracing NUVL's Cash from Financing Activities over 5 years: stood at $248.7 million in 2022, then jumped by 34.08% to $333.4 million in 2023, then plunged by 97.45% to $8.5 million in 2024, then surged by 5791.0% to $500.3 million in 2025, then sank by 98.04% to $9.8 million in 2026.
  • The last three Cash from Financing Activities figures came in at $9.8 million (Q1 2026), $500.3 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Nuvalent 9.75 Bn 9.75 Bn - 9.80 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 9.80 Mn
Dec 31, 2025 500.26 Mn
Sep 30, 2025 4.77 Mn
Jun 30, 2025 5.76 Mn
Mar 31, 2025 4.55 Mn
Dec 31, 2024 8.49 Mn
Sep 30, 2024 550.27 Mn
Jun 30, 2024 4.14 Mn
Mar 31, 2024 5.99 Mn
Dec 31, 2023 333.42 Mn
Sep 30, 2023 2.14 Mn
Jun 30, 2023 1.30 Mn
Mar 31, 2023 -17,000.00
Dec 31, 2022 248.67 Mn
Sep 30, 2022 1.01 Mn
Jun 30, 2022 5,000.00
Mar 31, 2022 -768,000.00
Dec 31, 2021 -944,000.00
Sep 30, 2021 174.93 Mn
Jun 30, 2021 134.23 Mn